263 related articles for article (PubMed ID: 32583431)
1. Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).
Maruyama D; Iida S; Ogawa G; Fukuhara N; Seo S; Miyazaki K; Yoshimitsu M; Kuroda J; Tsukamoto N; Tsujimura H; Hangaishi A; Yamauchi T; Utsumi T; Mizuno I; Takamatsu Y; Nagata Y; Minauchi K; Ohtsuka E; Hanamura I; Yoshida S; Yamasaki S; Suehiro Y; Kamiyama Y; Tsukasaki K; Nagai H
Br J Haematol; 2021 Feb; 192(3):531-541. PubMed ID: 32583431
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.
Ogawa Y; Suzuki K; Sakai A; Iida S; Ogura M; Tobinai K; Matsumoto M; Matsue K; Terui Y; Ohashi K; Ishii M; Mukai HY; Ando K; Hotta T
Cancer Sci; 2013 Jul; 104(7):912-9. PubMed ID: 23574271
[TBL] [Abstract][Full Text] [Related]
3. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Mateos MV; Bringhen S; Richardson PG; Lahuerta JJ; Larocca A; Oriol A; Boccadoro M; García-Sanz R; Di Raimondo F; Esseltine DL; van de Velde H; Desai A; Londhe A; San Miguel JF; Palumbo A
Haematologica; 2014 Jun; 99(6):1114-22. PubMed ID: 24763402
[TBL] [Abstract][Full Text] [Related]
5. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
6. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
[TBL] [Abstract][Full Text] [Related]
7. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ishida T; Kimura H; Ozaki S; Kubo K; Sunami K; Takezako N; Fujita H; Hayashi T; Kiguchi T; Ohashi K; Yamamoto S; Takamatsu H; Kosugi H; Ohta K; Sakai R; Handa H; Kondo S; Abe Y; Omoto E; Mitani K; Morita S; Murakami H; Shimizu K
Ann Hematol; 2020 May; 99(5):1063-1072. PubMed ID: 32248251
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
9. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
Lee SR; Choi H; Lee BH; Kang KW; Yu ES; Kim DS; Park Y; Choi CW; Kim BS; Sung HJ
Korean J Intern Med; 2019 Nov; 34(6):1333-1346. PubMed ID: 30360024
[TBL] [Abstract][Full Text] [Related]
10. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Mateos MV; Oriol A; Martínez-López J; Teruel AI; Bengoechea E; Palomera L; de Arriba F; Esseltine DL; Cakana A; Pei L; van de Velde H; Miguel JS
Ann Hematol; 2016 Dec; 95(12):2033-2041. PubMed ID: 27738789
[TBL] [Abstract][Full Text] [Related]
11. HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1).
Ri M; Iida S; Maruyama D; Sakabe A; Kamei R; Nakashima T; Tohkin M; Osaga S; Tobinai K; Fukuhara N; Miyazaki K; Tsukamoto N; Tsujimura H; Yoshimitsu M; Miyamoto K; Tsukasaki K; Nagai H
Cancer Sci; 2021 Dec; 112(12):5011-5019. PubMed ID: 34626515
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Lee JH; Moreau P; Niesvizky R; Dimopoulos M; Hajek R; Pour L; Jurczyszyn A; Qiu L; Klippel Z; Zahlten-Kumeli A; Osman M; Paiva B; San-Miguel J
Blood; 2019 May; 133(18):1953-1963. PubMed ID: 30819926
[TBL] [Abstract][Full Text] [Related]
13. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Martín Ramos ML; Oriol A; Bargay J; Bengoechea E; González Y; Pérez de Oteyza J; Gironella M; Encinas C; Martín J; Cabrera C; Paiva B; Cedena MT; Puig N; Bladé J; Lahuerta JJ; San-Miguel J
Blood; 2016 Jan; 127(4):420-5. PubMed ID: 26500339
[TBL] [Abstract][Full Text] [Related]
14. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
[TBL] [Abstract][Full Text] [Related]
17. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Mateos MV; Richardson PG; Dimopoulos MA; Palumbo A; Anderson KC; Shi H; Elliott J; Dow E; van de Velde H; Niculescu L; San Miguel JF
Am J Hematol; 2015 Apr; 90(4):314-9. PubMed ID: 25557740
[TBL] [Abstract][Full Text] [Related]
18. [Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)].
Ogiya D; Shibayama H; Nakatani E; Ando K; Suzuki K; Kuroda Y; Uchida T; Maruyama D; Matsumoto M; Matsue K; Iida S; Terui Y; Ri M; Chou T; Aotsuka N; Tabata S; Konishi J; Ohashi K; Shinagawa A; Sugiura I; Kuroda J; Miyamoto T; Ogura M; Tobinai K; Kanakura Y; Hotta T
Rinsho Ketsueki; 2016; 57(11):2311-2318. PubMed ID: 27941278
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
